Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.59 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.47 |
| ▸ | BRD2 | P25440 | 1/20 | 0.47 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.47 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.47 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17492711 | 0.89 | BRD4 (0.62) | BRD4BRD2BRD3BRDT | |
| SCHEMBL16010149 | 0.84 | BRD4 (0.72) | BRD4TRIM24BRD2BRD3BRDT | |
| SCHEMBL16009996 | 0.82 | BRD4 (0.40) | BRD4BRD2BRD3BRDT | |
| SCHEMBL16150295 | 0.80 | BRD4 (0.46) | BRD4BRD2BRD3BRDT | |
| SCHEMBL17492579 | 0.80 | BRD4 (0.42) | BRD4BRD2BRD3BRDT | |
| SCHEMBL16048714 | 0.77 | BRD4 (0.77) | BRD4BRD2BRD3BRDT | |
| SCHEMBL17492728 | 0.76 | BRD4 (0.65) | BRD4BRD2BRD3BRDT | |
| SCHEMBL16009470 | 0.75 | BRD4 (1.00) | BRD4 | |
| SCHEMBL16046127 | 0.74 | BRD4 (1.00) | BRD4TRIM24BRD2BRD3BRDT | |
| SCHEMBL16010183 | 0.74 | CNR1 (0.39) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237084-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | ABBVIE INC (US) | 2016-08-18 | — | — | US | claimed |
| US-9321764-B2 | Dihydro-pyrrolopyridinone inhibitors | ABBVIE INC. (US) | 2016-04-26 | — | — | US | claimed |
| US-20140275026-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | ABBVIE INC. | 2014-09-18 | — | — | US | claimed |
| EP-2970285-B1 | FUSED TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20160237084-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | ABBVIE INC (US) | 2016-08-18 | — | — | US | disclosed |
| US-9321764-B2 | Dihydro-pyrrolopyridinone inhibitors | ABBVIE INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150150884-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2015-06-04 | — | — | US | disclosed |
| US-8980879-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140275026-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | ABBVIE INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140256710-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150884-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | BRD4 1/4885TRIM24 1986/4885BRD2 4/4885 |
| US-20160237084-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | DPYD, QDPR, DHFR | BRD4 676/4885TRIM24 3092/4885BRD2 2475/4885 |
| US-20140256710-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | BRD4 1/4885TRIM24 1986/4885BRD2 4/4885 |
| US-20140275026-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | DPYD, QDPR, DHFR | BRD4 676/4885TRIM24 3092/4885BRD2 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.